Literature DB >> 7909520

The multidrug-resistance-reverser verapamil interferes with cellular P-glycoprotein-mediated pumping of daunorubicin as a non-competing substrate.

E C Spoelstra1, H V Westerhoff, H M Pinedo, H Dekker, J Lankelma.   

Abstract

We examined P-glycoprotein-mediated verapamil transport, using two drug-sensitive and multi-drug resistant cell-line couples, i.e. A2780, 2780AD and SW-1573, SW-1573/1R500. The interaction of 3H-labeled verapamil with cells was measured using a flow-through system. The verapamil-containing medium was pumped over the cells and monitored on-line for radioactivity. In the P-glycoprotein-expressing cells, verapamil accumulation was increased by vinblastine and some known multidrug resistant (MDR) modifiers. Subsequent removal of these modifiers caused release of verapamil into the medium against a verapamil concentration gradient. In this manner, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein. Using the flow-through system, we also exposed the cells to flowing culture medium containing daunorubicin, and measured the inhibition of daunorubicin efflux by verapamil. We found that, although the active efflux of daunorubicin was maximally blocked by verapamil short-term, longer-term active efflux of daunorubicin resumed. At a daunorubicin concentration in the flowing medium of 5 microM, increasing the verapamil concentration resulted in the same short-term effects, but in a significantly longer period of a maximal inhibition of daunorubicin efflux from the cells. At a daunorubicin concentration of 20 microM, increasing the verapamil concentration affected neither the short-term nor the long-term effects. These and other observations are in agreement with a model in which daunorubicin and verapamil are non-competing substrates for P-glycoprotein. In conclusion, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein and that verapamil and daunorubicin are non-competing substrates for P-glycoprotein. Consequently, the effectiveness of verapamil as an MDR antagonist may be compromised because it is extruded by P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909520     DOI: 10.1111/j.1432-1033.1994.tb18748.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  18 in total

Review 1.  Molecular properties of bacterial multidrug transporters.

Authors:  M Putman; H W van Veen; W N Konings
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

Review 2.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

3.  Molecular dissection of dual pseudosymmetric solute translocation pathways in human P-glycoprotein.

Authors:  Zahida Parveen; Thomas Stockner; Caterina Bentele; Sandra Pferschy; Martin Kraupp; Michael Freissmuth; Gerhard F Ecker; Peter Chiba
Journal:  Mol Pharmacol       Date:  2010-12-21       Impact factor: 4.436

4.  A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions.

Authors:  Matthew H Crouthamel; Daniel Wu; Ziping Yang; Rodney J Y Ho
Journal:  AAPS J       Date:  2010-07-10       Impact factor: 4.009

5.  Multiple Drug Transport Pathways through Human P-Glycoprotein.

Authors:  James W McCormick; Pia D Vogel; John G Wise
Journal:  Biochemistry       Date:  2015-07-10       Impact factor: 3.162

6.  Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.

Authors:  C Dagenais; J Zong; J Ducharme; G M Pollack
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

7.  Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium.

Authors:  J Huwyler; J Drewe; C Klusemann; G Fricker
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  Evidence against a role of P-glycoprotein in the clearance of the Alzheimer's disease Aβ1-42 peptides.

Authors:  Ivan Bello; Milena Salerno
Journal:  Cell Stress Chaperones       Date:  2015-01-16       Impact factor: 3.667

9.  The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein.

Authors:  C Martin; G Berridge; P Mistry; C Higgins; P Charlton; R Callaghan
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

10.  Membrane interactions of some catamphiphilic drugs and relation to their multidrug-resistance-reversing ability.

Authors:  I K Pajeva; M Wiese; H P Cordes; J K Seydel
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.